The latest market report published by Credence Research, Inc. “The paroxysmal nocturnal hemoglobinuria (PNH) market was valued at $2,341.4 million in 2018 and is expected to reach $6,203.0 million by 2027, with a compounded annual growth rate (CAGR) of 11.7% projected from 2019 to 2027.”.
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and life-threatening blood disorder characterized by the destruction of red blood cells. It results from a genetic mutation leading to an absence or reduction of protective proteins on the surface of red blood cells, making them vulnerable to complement attack. Patients suffering from PNH often experience symptoms such as fatigue, abdominal pain, difficulty swallowing, and blood clots. The condition can also lead to complications like kidney disease and life-threatening blood clots.
Market Dynamics
The PNH market has witnessed a considerable shift in recent years. Rising awareness about rare diseases, increased diagnosis rates, and technological advancements in genetic testing have contributed to this growth. Furthermore, the entry of novel therapies targeting the complement pathway has fueled the expansion of the market. These treatments aim to reduce hemolysis, alleviate symptoms, and improve the quality of life for patients with PNH.
Key Players & Innovation
The PNH therapeutic landscape is dominated by a few key players. Alexion Pharmaceuticals, with its product eculizumab (Soliris), was the first complement inhibitor approved for PNH treatment and had, for years, enjoyed a monopoly. However, new entrants, like Apellis Pharmaceuticals with pegcetacoplan (Empaveli), are offering alternatives that promise enhanced efficacy and better patient outcomes.
These advancements are not just limited to complement inhibitors. Companies are also exploring gene therapy and stem cell transplantation to offer potentially curative treatments for PNH.
Challenges & Opportunities
While the introduction of new therapies has undoubtedly benefitted patients, the high cost of these treatments has been a significant barrier to access for many. Most complement inhibitors come with a hefty price tag, often reaching hundreds of thousands of dollars annually per patient. This has sparked debates on drug pricing, insurance coverage, and reimbursement policies.
Browse the Full Report: https://www.credenceresearch.com/report/paroxysmal-nocturnal-hemoglobinuria-market
On the brighter side, the increased focus on PNH has opened doors for research funding, drug development, and collaborations between pharmaceutical companies and academic institutions. The rising incidence of PNH diagnosis, coupled with the unmet medical needs of these patients, offers a vast market opportunity for new entrants. Companies that can provide effective, safer, and more affordable treatment options will likely capture a more significant market share in the coming years.
Future Outlook
The PNH market is poised for growth, driven by an increase in disease awareness, advanced diagnostic methods, and the entrance of new and innovative treatments. As our understanding of the disease deepens, it’s anticipated that more targeted therapies with better safety and efficacy profiles will emerge.
Collaboration between patient advocacy groups, researchers, and pharmaceutical companies will be crucial in steering the direction of the market. The ultimate goal remains clear: to provide PNH patients with a wider array of treatment options, improve their quality of life, and potentially find a cure for this devastating disease.
List of Companies Covered:
Alexion Pharmaceuticals, Takeda Pharmaceutical Company Limited (Shire Plc), Akari Therapeutics, Apellis Pharmaceuticals, Ra Pharmaceuticals, Achillion Pharmaceuticals, Amgen Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG.
By Treatment Type
- Medication
- Stem Cell Transplant
- Blood Transfusion
By Geography Segment Type
- North America (U.S. and Rest of North America)
- Europe (U.K., Germany, France, and Rest of Europe)
- Asia Pacific (Japan, China, India, and Rest of Asia Pacific)
- Rest of World (Middle East & Africa (MEA), Latin America)
Contact Us:
Office No 3 Second Floor,
Abhilasha Bhawan, Pinto Park,
Gwalior [M.P]
474005 India
Phone: +91 6232 49 3207
Email: sales@credenceresearch.com
Visit: https://www.credenceresearch.com/